Hormel Foods Corp vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Hormel Foods Corp trades at $20.07 (market cap $10.90B), while Ionis Pharmaceuticals Inc. Common Stock trades at $43.32 (market cap $7.10B). The key difference: Hormel Foods Corp is the larger of the two by market cap, and Hormel Foods Corp pays a 5.91% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| HRL | IONS | |
|---|---|---|
Market Cap | $10.90B | $7.10B |
Volume | 5,843,624 | 2,027,457 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $86.50 |
52-Week Low | $19.19 | $42.38 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $12.89B | $6.66B |
Dividend Yield | 5.91% | — |
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.21, down 0.47% with a bearish technical outlook. The stock shows mixed fundamentals with declining net margins (2.82% in 2026) but consistent earnings beats and a $1.06B Brakebush acquisition to expand foodservice presence. Valuation metrics include a P/E of 30.98 and P/S of 0.87, while analyst consensus is cautious with 20% buy ratings.
Investment outlook balances dividend stability (60-year growth streak) against margin pressures and acquisition integration risks. The consensus price target of $25 offers 30% upside, but weak technicals and shrinking dividend raises warrant caution. Key catalysts include Brakebush synergies and foodservice growth execution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →